Figure 4
Kaplan–Meier analysis of lethal arrhythmic event-free survival during follow-up in Brugada syndrome cohort-I. (A) Lethal arrhythmic event-free survival during the follow-up period in Brugada syndrome probands carrying SCN5A rare variations (all SCN5A; n = 60) and SCN5A(−) (n = 355). Confidence bands indicate 95% pointwise CI. (B) Time course of Brugada syndrome patients with loss-of-function SCN5A mutations (n = 45) and non-loss of function (n = 15). Non-loss-of-function probands have no lethal arrhythmic events during the follow-up period. (C) Lethal arrhythmic event-free survival of loss of function (n = 45) vs. non-loss of function plus SCN5A(−) (n = 370). The dissociation between two survival curves is more pronounced than that in panel A.

Kaplan–Meier analysis of lethal arrhythmic event-free survival during follow-up in Brugada syndrome cohort-I. (A) Lethal arrhythmic event-free survival during the follow-up period in Brugada syndrome probands carrying SCN5A rare variations (all SCN5A; n = 60) and SCN5A(−) (n = 355). Confidence bands indicate 95% pointwise CI. (B) Time course of Brugada syndrome patients with loss-of-function SCN5A mutations (n = 45) and non-loss of function (n = 15). Non-loss-of-function probands have no lethal arrhythmic events during the follow-up period. (C) Lethal arrhythmic event-free survival of loss of function (n = 45) vs. non-loss of function plus SCN5A(−) (n = 370). The dissociation between two survival curves is more pronounced than that in panel A.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close